-
FDA fast-tracks Sangamo/Pfizer hemophilia A treatment
WASHINGTON — Sangamo Therapeutics announced on Tuesday that the Food and Drug Administration has granted Fast Track designation to SB-525, the company's clinical stage cDNA gene therapy candidate for hemophilia A, which is being developed as part of an exclusive, global collaboration and license agreement with Pfizer.
The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill an unmet medical need.